Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 15/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29599257 | 1.00 | CFTR (0.57) | CFTRMAPTPDE4D | |
| SCHEMBL26846043 | 0.83 | CFTR (0.69) | CFTR | |
| SCHEMBL30315211 | 0.82 | CFTR (0.58) | CFTRPDE4D | |
| SCHEMBL27244533 | 0.82 | CFTR (0.58) | CFTRPDE4D | |
| SCHEMBL29470999 | 0.81 | KDM4E (0.73) | CFTR | |
| SCHEMBL24370745 | 0.81 | KDM4E (0.73) | CFTR | |
| SCHEMBL24370553 | 0.81 | CFTR (0.75) | CFTR | |
| SCHEMBL29599158 | 0.81 | CFTR (0.75) | CFTR | |
| SCHEMBL24370783 | 0.80 | CFTR (0.71) | CFTR | |
| SCHEMBL28908247 | 0.80 | CFTR (0.56) | CFTRPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199623-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CFTR MODULATORS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-06-20 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-11-28 | — | — | US | disclosed |
| EP-4232451-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | Ildong Pharmaceutical Co., Ltd. (KR) | 2023-08-30 | — | — | EP | disclosed |
| WO-2023067388-A1 | USES OF CFTR MODULATOR AND/OR PDE4 INHIBITOR COMPOUNDS | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2023-04-27 | — | — | WO | disclosed |
| US-20230080486-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | S2CBIO INC. (KR) | 2023-03-16 | — | — | US | disclosed |
| WO-2022084741-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022084741-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827640-B2 | Substituted pyrazolo[1,5-a]pyrimidines as CFTR modulators | PDE4A, PDE4B, PDE5A | CFTR 4/4885MAPT 4661/4885PDE4D 9/4885 |
| US-20230080486-A1 | CFTR MODULATOR COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CFTR, PDE4A, PDE6C | CFTR 1/4885MAPT 4655/4885PDE4D 9/4885 |
| US-20240199623-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINES AS CFTR MODULATORS | PDE4A, PDE4B, PDE6C | CFTR 4/4885MAPT 4636/4885PDE4D 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.